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Abstract
Introduction The purpose of this study was to assess the
accuracy of N-terminal-pro-B-type natriuretic peptide (NT-
proBNP) as a diagnostic tool to recognize acute respiratory
failure of cardiac origin in an unselected cohort of critically ill
patients.
Methods We conducted a prospective observational study of
medical ICU patients. NT-proBNP was measured at ICU
admission, and diagnosis of cardiac dysfunction relied on the
patient's clinical presentation and echocardiography.
Results Of the 198 patients included in this study, 102 (51.5%)
had evidence of cardiac dysfunction. Median NT-proBNP
concentrations were 5,720 ng/L (1,430 to 15,698) and 854 ng/
L (190 to 3,560) in patients with and without cardiac
dysfunction, respectively (P < 0.0001). In addition, NT-proBNP
concentrations were correlated with age (ρ = 0.43, P < 0.0001)
and inversely correlated with creatinine clearance (ρ = -0.58, P
< 0.0001). When evaluating the performance of NT-proBNP
concentrations to detect cardiac dysfunction, the area under the
receiver operating characteristic (ROC) curve was 0.76 (95%
confidence interval (CI) 0.69 to 0.83). In addition, a stepwise
logistic regression model revealed that NT-proBNP (odds ratio
(OR) = 1.01 per 100 ng/L, 95% CI 1.002 to 1.02),
electrocardiogram modifications (OR = 11.03, 95% CI 5.19 to
23.41), and severity assessed by organ system failure score
(OR = 1.63 per point, 95% CI 1.17 to 2.41) adequately
predicted cardiac dysfunction. The area under the ROC curve of
this model was 0.83 (95% CI 0.77 to 0.90).
Conclusions NT-proBNP measured at ICU admission might
represent a useful marker to exclude cardiac dysfunction in
critically ill patients.
Introduction
B-type (brain) natriuretic peptide (BNP) is a neurohormone
that is secreted in response to volume expansion and pressure
overload of cardiac ventricles. It has been reported that meas-
urements of BNP and N-terminal-pro-B-type natriuretic pep-
tide (NT-proBNP) are sensitive and specific tests for the
diagnosis of heart failure in the urgent care setting [1-6]. In
addition, BNP measurement was shown to be superior to clin-
ical judgment in the identification of cardiac heart failure,
regardless of the threshold value [7]. However, BNP concen-
trations frequently are elevated in critically ill patients, and sev-
eral pre-existing conditions, including advanced age and renal
failure, might influence BNP concentration [4]. Few studies
have addressed the diagnostic value of natriuretic peptides in
the ICU. This preliminary study aimed to evaluate the accuracy
of NT-proBNP measured at admission to the ICU as a marker
of cardiac dysfunction in a heterogeneous group of critically ill
patients. The secondary objective of this study was to evaluate
the impact of age and creatinine clearance on the performance
of NT-proBNP as a diagnostic marker.
BNP: B-type natriuretic peptide; CI: confidence interval; ECG: electrocardiogram; EF: ejection fraction; ICU: intensive care unit; IRB: institutional 
review board; LH: likelihood ratio; LV: left ventricular; NT-proBNP: N-terminal-pro-B-type natriuretic peptide; OR: odds ratio; OSF: organ system fail-
ure; ROC: receiver operating characteristic.Critical Care    Vol 12 No 6    Coquet et al.
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Materials and methods
Patients
We prospectively included consecutive adult patients (> 18
years old) who were admitted to the medical ICU of the Dijon
Hospital between 1 September 2003 and 31 March 2004.
Patients with end-stage chronic renal failure (that is, patients
with chronic renal failure requiring renal replacement therapy)
were excluded from the study. This study was approved by our
institutional review board (IRB), and each of the included
patients or next of kin received written information and gave
oral consent. Our IRB waived the need for written consent.
NT-proBNP measurement
Plasma levels of NT-proBNP were measured with the Elecsys
Electro-chemo luminescent assay (Elecsys 2010; Roche
Diagnostics, Basel, Switzerland) according to National Com-
mittee for Clinical Laboratory Standards guidelines and Inter-
national Federation of Clinical Chemistry and Laboratory
Medicine quality specifications for BNP methods. This test
had a coefficient of variations of 3.2% to 2.4%, from 175 to
4,962 ng/L, with an analytical range of 5 to 35,000 ng/L.
Diagnoses
Cardiac dysfunction was defined as any degree of respiratory
insufficiency (acute or acute on chronic hypoxemia requiring
oxygen therapy or mechanical ventilation) caused by a systolic
or diastolic cardiac failure that requires inotropic drugs and/or
diuretics. Diagnoses were based on clinical and radiographic
findings and were validated by an echocardiography per-
formed in each of the patients. These diagnoses were vali-
dated by two of the authors (IC and J-PQ) at the time of patient
discharge. These physicians were unaware of the NT-proBNP
measurement results. Echocardiography was performed in
each of the patients. Left ventricular (LV) volumes were meas-
ured in the apical four-chamber view with the area-length
method. The LV ejection fraction (EF) was calculated with
standard formulas. Systolic LV dysfunction was defined as an
EF of less than 50%. In patients with conserved LV EF, the evi-
dence for diastolic dysfunction was considered as a docu-
mented cardiac dysfunction. To evaluate diastolic function, the
thickness of the septal and posterior walls of the left ventricle
and its internal dimensions were measured. The transmitral
flow velocity was measured with the use of pulsed-wave Dop-
pler, and the peak velocities of the E wave and A wave were
measured. The ratio of these velocities, the E-wave decelera-
tion time, and the isovolumetric relaxation time were measured
in order to detect diastolic dysfunction. Electrocardiogram
(ECG) modifications were defined as ST changes or T-wave
inversion. Acute renal failure was defined by creatinine clear-
ance, which was calculated at ICU admission with the Cock-
roft-Gault formula. Simplified Acute Physiology Score II
(SAPS II) and organ system failure (OSF) score were calcu-
lated at admission [8,9]. Sepsis was diagnosed by using the
criteria developed at the American College of Chest Physi-
cians/Society of Critical Care Medicine consensus confer-
ences [10]. Individual organ failure was defined according to
the OSF score [8].
Statistical analysis
Results were reported as medians and quartiles (interquartile
ranges) or as numbers (percentages). Categorical variables
were compared by using the chi-square test or Fisher exact
test, and continuous variables were compared by using the
non-parametric Wilcoxon test or the Mann-Whitney test.
Logistic regression analyses were performed to identify varia-
bles that were associated significantly with cardiac dysfunc-
tion, as measured by the estimated odds ratio (OR) with 95%
confidence interval (CI). Variables yielding P values of less
than 0.20 in the bivariate analyses were entered into a forward
stepwise logistic regression model in which cardiac dysfunc-
tion was the variable of interest. The covariates were entered
into the model with critical removal P values of 0.1. Colinearity
and interactions were tested. The Hosmer-Lemeshow test
was used to check goodness-of-fit of the logistic regression.
A receiver operating characteristic (ROC) curve that depicted
the relationship between the proportion of true positives and
the proportion of false positives was drawn, depending on the
prediction rule used to classify the patients as having cardiac
dysfunction. A 2 × 2 table was calculated to determine the
sensitivity and specificity. Cutoff values, which were defined
as the threshold values that maximized the sum of sensitivity
and specificity, were determined for each score with the ROC
curves. The positive likelihood ratio (LH) was computed to fur-
ther evaluate the test performance. Indeed, in order to depict
the input of NT-proBNP more precisely, we computed the LH
in order to describe its ability to modify probabilities of having
a specific diagnosis (prevalence of the disease in a specific
population, for example) before the result of a test is known
(named pre-test probability) into a post-test probability, which
takes the result of the test into account [11,12]. All tests were
two-sided, and P values of less than 0.05 were considered
statistically significant. Statistical tests were performed with
the SAS 6.12 software package (SAS Institute Inc., Cary, NC,
USA).
Results
Between September 2003 and March 2004, 198 consecutive
patients fulfilled the inclusion criteria. Patient characteristics
are summarized in Table 1. Median NT-proBNP concentra-
tions were 5,720 ng/L (1,430 to 15,698) and 854 ng/L (190
to 3,560) in patients with and without cardiac dysfunction,
respectively (P < 0.0001). In addition, NT-proBNP concentra-
tions were correlated with age (ρ = 0.43, P < 0.0001) and
inversely correlated with creatinine clearance (ρ = -0.58, P <
0.0001) (Figures S1 and S2 of Additional data file 1).
The area under the ROC curve was 0.76 (95% CI 0.69 to
0.83) (Figure 1). Performance of NT-proBNP in patients with
and without acute renal failure is reported in Additional data
file 1 (Figure S3a, S3b). In the overall population of patients,Available online http://ccforum.com/content/12/6/R137
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Table 1
Patient characteristics and factors associated with cardiac dysfunction at intensive care unit admission
Variables All patients Cardiac dysfunction No cardiac dysfunction Odds ratio 95% CI P value
n = 198 n = 102 n = 96
Male gender 130 (65.7%) 70 (68.6%) 60 (62.5%) 1.31 0.72–2.36 0.36
Age 67 (53–77) 73.5 (60–79) 58.5 (45–72) 1.04 1.02–1.06 < 0.0001
< 50 years 31 (15.7%) 8 (7.8%) 23 (24.0%) 0.27 0.11–0.64 0.003
50–70 years 78 (39.4%) 34 (33.3%) 44 (45.8%) 0.59 0.33–1.05 0.07
> 70 years 89 (44.9%) 60 (58.8%) 29 (30.2%) 3.30 1.83–5.94 < 0.0001
SAPS II at ICU admission [9] 37 (26–58) 45 (30–65) 32 (22–50) 1.03 1.01–1.04 0.0001
OSF score at ICU admission [8] 1 (0–2) 1 (0–2) 1 (0–1) 1.62 1.21–2.16 0.0001
Comorbidities
Chronic cardiac failure 42 (21.2%) 28 (27.5%) 14 (14.6%) 2.22 1.08–4.53 0.29
Chronic renal failure 101 (51.0%) 64 (62.7%) 37 (34.7%) 3.01 1.65–5.48 0.0003
Creatinine clearance, mL/minute 48 (25–76) 36 (11–65) 50 (37–96) 0.98 0.98–0.99 0.0006
Organ failure according to OSF 
score
Cardiovascular 50 (25.2%) 36 (35.3%) 14 (14.6%) 3.74 1.57–6.39 0.001
Respiratory 63 (31.8%) 38 (37.2%) 25 (26.0%) 1.66 0.90–3.07 0.10
Renal 50 (25.2%) 34 (33.3%) 16 (16.7%) 2.48 1.26–4.89 0.008
Neurological 43 (21.7%) 27 (26.5%) 16 (16.7%) 1.78 0.88–3.57 0.10
Hepatic 8 (4.0%) 4 (3.9%) 4 (3.1%) 0.93 0.22–3.82 0.91
Clinically documented infection 73 (36.9%) 38 (37.2) 35 (36.4%) 0.99 0.55–1.79 0.98
NT-proBNP per 100 ng/L 26.3 (4.7–73.0) 57.2 (14.3–157.0) 8.5 (1.9–35.6) 1.01 1.01–1.02 < 0.0001
Troponin (ng/mL) 0.10 (0.02–0.44) 0.16 (0.05–1.1) 0.06 (0.01–0.21) 1.39 1.03–1.88 0.03
ECG modifications 92 (46.5%) 75 (73.5%) 17 (17.7%) 12.90 6.51–25.59 < 0.0001
C-reactive protein (mg/L) 186 (78–332) 234 (84–370) 156 (74–223) 1.003 0.98–1.01 0.3
Inotropic agents 43 (21.7%) 40 (39.2%) 3 (3.1%) 20 5.92–67.51 < 0.0001
Vasopressive agents 52 (26.3%) 37 (36.3%) 15 (15.6%) 3.74 1.55–6.86 0.0013Critical Care    Vol 12 No 6    Coquet et al.
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NT-proBNP of less than 500 ng/L predicted the absence of
cardiac dysfunction with a sensitivity of 89% and a specificity
of 43%. In accordance with the obtained LHs (positive LH =
1.55, negative LH = 0.25), Figure 2 depicts the ability of an
NT-proBNP to modify probabilities of having a cardiac dys-
function and therefore to convert the estimated probability of
the suspected diagnosis before the test result was known
(pre-test probability) into a post-test probability, which takes
the result into account. For example, for a pre-test probability
of having a cardiac dysfunction of 20%, a negative result of the
enzyme-linked immunosorbent assay test for NT-proBNP
would produce a post-test probability of 5.8%. Conversely, for
a pre-test probability of 70%, a negative result would yield a
post-test probability of 37%.
In addition, a stepwise logistic regression model revealed that
NT-proBNP (OR = 1.01 per 100 ng/L, 95% CI 1.002 to 1.02),
ECG modifications (OR = 11.03, 95% CI 5.19 to 23.41), and
OSF score (OR = 1.63 per point, 95% CI 1.17 to 2.41) ade-
quately predicted cardiac dysfunction. The goodness-of-fit of
the model was acceptable (Hosmer-Lemeshow: χ2 = 5.27,
degrees of freedom = 8, P = 0.728), and the area under the
ROC curve of this model was 0.834 (95% CI 0.77 to 0.90).
When age, creatinine clearance, troponin, or sepsis was
forced into the final model, these variables did not change the
model. Lastly, in our study, NT-ProBNP was not independently
associated with outcome (Table S1 and Figure S4 of Addi-
tional data file 1).
Discussion
This study, which is the largest of its kind in critically ill
patients, demonstrates the relevance of NT-proBNP in the
Length of ICU stay, days 3 (1–8) 4 (1–10) 3 (1–6) 1.17 0.98–1.52 0.34
Length of hospital stay, days 10 (3–21) 11 (4.5–23.5) 10 (3–20) 1.01 0.99–1.01 0.39
ICU mortality 47 (23.7%) 35 (34.3%) 12 (12.5%) 3.65 1.76–7.59 0.0005
Hospital mortality 72 (36.3%) 52 (51%) 20 (20.8%) 3.95 2.1–7.4 < 0.0001
Data are presented as medians and quartiles (interquartile ranges) or as numbers (percentages). CI, confidence interval; ECG, electrocardiogram; 
ICU, intensive care unit; NT-proBNP, N-terminal-pro-B-type natriuretic peptide; OSF, organ system failure [8]; SAPS II, Simplified Acute 
Physiology Score II [9].
Table 1 (Continued)
Patient characteristics and factors associated with cardiac dysfunction at intensive care unit admission
Figure 1
Receiver operating characteristic (ROC) curve for N-terminal-pro-B- type natriuretic peptide (NT-proBNP) in the entire cohort of critically ill  patients Receiver operating characteristic (ROC) curve for N-terminal-pro-B-
type natriuretic peptide (NT-proBNP) in the entire cohort of critically ill 
patients. The ROC curve depicts the relationship between the propor-
tion of true positives (Sensitivity) and the proportion of false positives (1 
– Specificity) of different thresholds of NT-proBNP concentrations 
when tested to predict cardiac dysfunction. Diagonal segments are 
produced by ties. The area under the ROC curve was 0.76 (95% confi-
dence interval 0.69 to 0.83).
Figure 2
Predictive value of N-terminal-pro-B-type natriuretic peptide (NT- proBNP) for cardiac dysfunction Predictive value of N-terminal-pro-B-type natriuretic peptide (NT-
proBNP) for cardiac dysfunction. The cutoff of retained NT-proBNP 
concentrations was 500 ng/L. The estimated post-test probabilities for 
different pre-test probabilities are shown, assuming constancy of the 
positive likelihood ratio for NT-proBNP of greater than 500 ng/L (Post-
test +) or of the negative likelihood ratio for NT-proBNP of less than 
500 ng/L (Post-test -). Pre-test probability and post-test probability 
were defined, respectively, as the probabilities of cardiac dysfunction 
before and after a diagnostic test (NT-proBNP) result was known.Available online http://ccforum.com/content/12/6/R137
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exclusion of cardiac dysfunction at ICU admission. However,
our study also confirms the variability of NT-proBNP in critically
ill patients and illustrates the limits to its interpretation.
Association of NT-proBNP with age and renal function
We investigated the possible effects of age and creatinine
clearance on NT-proBNP levels. The presence of renal insuffi-
ciency or advanced age was correlated with NT-proBNP con-
centration. This finding is consistent with previous reports [4].
We showed that, despite the effects of age and creatinine
clearance on NT-proBNP levels, a single measurement of the
NT-proBNP level at ICU admission might rule out cardiac dys-
function in this population, independently of age or renal
function.
Performance of NT-proBNP
Over the past decade, several studies have indicated that car-
diac dysfunction is a frequent and important factor that deter-
mines the outcome of critically ill patients [13]. It has been
estimated that as many as 15% to 30% of ICU admissions are
complicated by some degree of myocardial injury and that as
many as 40% of patients with severe sepsis have cardiac dys-
function. Therefore, measurement of NT-proBNP might be a
useful tool to rule out cardiac dysfunction. However, this large
cohort study confirms the large dispersion of NT-proBNP val-
ues at ICU admission. Indeed, NT-proBNP levels are higher
and more variable in our study than in selected populations of
patients with ischemic heart disease or in the emergency
department [13,14]. This fact might explain the relatively poor
positive predictive value in our study. In addition, our results
confirm that careful evaluation of the pre-test probability is
required to interpret the NT-proBNP measurement correctly.
Limits
Our study has several limitations. First, the decision to evaluate
a non-selected population of critically ill patients might be crit-
icized. Indeed, the selection of patients on the basis of reason
for ICU admission or of suspected cardiac dysfunction might
modify the incidence of cardiac dysfunction and, therefore, the
levels of NT-proBNP. However, the objective of this study was
to evaluate NT-proBNP at ICU admission and not in a selected
population of patients with acute respiratory failure. Another
limitation is the interpretation of creatinine clearance in the
ICU. Although we agree that several biases limit the interpre-
tation of such evaluations of renal function, our results show an
association between calculated creatinine clearance and NT-
proBNP levels and are in accordance with those of previous
studies [15,16]. Echocardiography was performed at various
times during ICU stay, including at discharge in several of the
patients. This design may have induced a bias and may have
led to an underestimation of the accuracy of the investigational
marker. Nevertheless, none of the included patients developed
any significant cardiac event that may have affected the results
of the echocardiography. Lastly, NT-proBNP was measured
only at ICU admission. Indeed, time course of NT-proBNP may
be interesting and helpful to diagnose cardiac dysfunction.
However, the main objective of this study was to evaluate the
diagnostic performance of the marker at ICU admission in an
unselected population of critically ill patients.
Conclusion
The present study, which examined a cohort of unselected
patients admitted to the ICU, indicates that NT-proBNP is use-
ful to exclude cardiac dysfunction in this population. However,
the high variability and dispersion of NT-proBNP values neces-
sitate careful evaluation of such biomarkers in this setting in
order to interpret the results correctly. Additional studies are
needed in order to evaluate time course of NT-proBNP in crit-
ically ill patients and to confirm our results.
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Key messages
￿  The presence of renal insufficiency or advanced age 
was correlated with N-terminal-pro-B-type natriuretic 
peptide (NT-proBNP) concentration.
￿  Despite this correlation, a single measurement of the 
NT-proBNP level at ICU admission allowed us to rule 
out cardiac dysfunction in the studied population, inde-
pendently of age or renal function.
￿  Our cohort study confirms the large dispersion of NT-
proBNP values at ICU admission in a non-selected pop-
ulation of critically ill patients.
￿  Careful evaluation of the pre-test probability is required 
to interpret the NT-proBNP measurement correctly.Critical Care    Vol 12 No 6    Coquet et al.
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